Acknowledgement to Referees

Dear Reader,

Welcome to the first issue of BioDrugs for 2023.

I wish to reflect on last year’s achievements, and to thank all those who have contributed their valuable time and effort to the journal over the past 12 months.

I would like to start by thanking the authors of the articles published in BioDrugs over the course of 2022. The skill and dedication of these experts is critical to the continued success of the journal.

The high quality of published article in BioDrugs has been reflected in the most recent Impact Factor of 7.744 and CiteScore™ of 10.5. These place the journal in the first quartile for Pharmacology and Pharmacy, Immunology, and Oncology in Clarivate Analytics, and 12th of 255 journals (95th percentile) in Medicine—Pharmacology in Scopus. Further, BioDrugs has published content in a timely manner, with an average time from submission to acceptance of 121 days in 2022.

The quality of published articles is also testament to the significant efforts of the peer reviewers, whose commitment ensures that the journal’s content is held to the highest possible standard. I would like to thank the following individuals who acted as reviewers for BioDrugs in the last 12 months:

Ivo Abraham, USA

Nancy Agmon-Levin, Israel

Mohammed I. Aladul, Iraq

Matthew Alexander, USA

Anna B. Almarsdottir, Denmark

Yasumasa Arai, Japan

Kazuhiro Araki, Japan

Yves Aubin, Canada

Alejandro Balsa, Spain

Andrea Becciolini, Italy

Francesco Bellinato, Italy

Luigi Bennardo, Italy

Inigo Bermejo, UK

Margaret Bermingham, Ireland

J. Edwin Blalock, USA

Andreas Blesl, Austria

John Botson, USA

Robert Brown, UK

Anna E. Bucsics, Austria

A. David Burden, UK

Johannes F. Buyel, Germany

Arturo Casadevall, USA

Jeffrey Chabot, USA

Shao-Chin Chiang, Taiwan, Republic of China

Arnon D. Cohen, Israel

Hillel P. Cohen, USA

Manuela Colucci, Italy

Paul Cornes, UK

Esteban Cruz, Australia

Pablo de la Cueva Dobao, Spain

John De Vos, France

Sosana Delimpasi, Greece

Montserrat Díaz-Encarnación, Spain

Dimiter S. Dimitrov, USA

Lene Dreyer, Denmark

Louise C. Druedahl, Denmark

Lars Edvinsson, Sweden

Ramon Eritja, Spain

Isabel Fabregat, Spain

Claudia Ferroni, Italy

Christopher B. Fox, USA

Yaacov Frishberg, Israel

Eleonore Fröhlich, Austria

Livio Garattini, Italy

Matthew Gardner, USA

Pere Gascon, Spain

Daniel Gaudet, Canada

Usama Gergis, USA

Salah Ghabri, France

Craig Giragossian, USA

Jerome Goldschmidt, USA

Joao Goncalves, Portugal

Miguel Ángel Gonzalez-Gay, Spain

Chester B. Good, USA

Anna Goodman, UK

Josep M. Grinyo, Spain

Sebastian Grosicki, Poland

Luisa Guidi, Italy

Wafa Hamdi, Tunisia

Lennart Hammarström, Sweden

Jurij Hanzel, Slovenia

Amir Hashemi-Meshkini, Islamic Republic of Iran

Philip N. Hawkins, UK

Michael R. Hayden, Canada

Kasper Hjuler, Denmark

James Hodgkinson, UK

Cheng-Yang Hsieh, Taiwan, Republic of China

Huei-Kai Huang, Taiwan, Republic of China

Davod Jafari, Islamic Republic of Iran

Gabor Jarvas, Hungary

Chelsee J. Jensen, USA

Thanigaivelan Kanagasabai, USA

Hye-Na Kang, Switzerland

Natasha Kekre, Canada

Audrius Kilikevicius, USA

Kyung Bo Kim, USA

Allison Kolbe, USA

Hans-Christian Kolberg, Germany

Cleo Kontoravdi, UK

Pekka Kurki, Finland

Byungsuk Kwon, Republic of Korea

Edward Chia-Cheng Lai, Taiwan, Republic of China

Augustin Latourte, France

George Lazaros, Greece

Mark G. Lebwohl, USA

Hyun Lee, Republic of Korea

Gemma Leon, Ireland

Xue Li, Hong Kong, China

Clifford Lingwood, Canada

Hwei San Loh, Malaysia

Stephanie Longet, UK

Danilo Malandrino, Italy

Tauqeer H. Mallhi, Saudi Arabia

Mario Mandala, Italy

David M. Markusic, USA

Paolo Martelletti, Italy

Peter J. McAllister, USA

Davide Melisi, Italy

Daniele Mengato, Italy

Eleonora Mezzaroma, USA

Dawn S. Milliner, USA

Markus Moehler, Germany

Giovanni Monteleone, Italy

Serafin Morales, Spain

Shinji Morimoto, Japan

Randall J. Mrsny, UK

Shuaib Nasser, UK

Ekaterina Nestorovich, USA

Dario Nieri, Italy

Lennart Nilsson, Sweden

Roman J. Nowicki, Poland

Hannah O'Farrell, Australia

Francisco Ortiz-Sanjuán, Spain

Sonia T. Oskouei, USA

Konstantinos Papamichael, USA

Vidhya Parameswaran, USA

William M. Pardridge, USA

Iga Pawłowska, Poland

Guillaume Piessen, France

Giulio Pisani, Italy

Stephanie Portelli, Malta

Anurag S. Rathore, India

William Redmond, USA

Abanoub Riad, Czech Republic

Simone Ribero, Italy

Leàn Rolfes, The Netherlands

Claudio Romano, Italy

Massimiliano Ruscica, Italy

Piotr Rutkowski, Poland

Joshua Sabari, USA

Farshid Sadeghipour, Switzerland

Vaishali Sanchorawala, USA

Kati Sarnola, Finland

Huub Schellekens, The Netherlands

Christian K. Schneider, Denmark

Gisbert W. Selke, Germany

Noriko Shimasaki, Singapore

Kamel R. Shoueir, Egypt

Gabriele Simonini, Italy

Mariana P. Socal, USA

Rocco Spagnuolo, Italy

James G. Stevenson, USA

Jan Steyaert, Belgium

Stephen J. Streatfield, USA

Janet Sultana, Malta

Aaron C. Tan, Singapore

Daniele Tauriello, The Netherlands

Klaus Tenbrock, Germany

David Ternant, France

Christian A. Thomas, USA

Robin Thorpe, UK

Songhai Tian, USA

Tycho Tromp, The Netherlands

Christopher J. Twelves, UK

Yannick Vandenplas, Belgium

Abhinav Vasudevan, USA

Bram Verstockt, Belgium

Gianni Virgili, Italy

Arnold G. Vulto, The Netherlands

Cornelius F. Waller, Germany

Sheng-Fan Wang, Taiwan, Republic of China

Xinshuai Wang, China

Christopher Webster, USA

Rebecca Webster, UK

Björn Wettermark, Sweden

Edward Wild, UK

Hao Xie, USA

Sarah Yim, USA

Weiming Yuan, USA

Aziz Zaanan, France

Yoshitaka Zenke, Japan

Wei Zhang, China

Guangrong Zheng, USA

Xiaobo Zhong, USA

Xiaoyue Zhu, USA

Through the hard work of our authors and reviewers, we continue to see great gains in article usage. The most popular 2022 articles to date, in terms of downloads from SpringerLink are:

• The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland

• Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies

• Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants

• Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic

• Interchangeability for Biologics is a Legal Distinction in the USA, Not a Clinical One

• Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy

• Therapeutic siRNA: State-of-the-Art and Future Perspectives

• Bioanalytical Methods and Strategic Perspectives Addressing the Rising Complexity of Novel Bioconjugates and Delivery Routes for Biotherapeutics

• Dengue Vaccines: An Update

• Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale

Social media sharing and other online mentions of information are other metrics with which to measure the reach of articles. In 2022, the following articles published in BioDrugs scored highly on the Altmetric system:

• Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies

• Therapeutic siRNA: State-of-the-Art and Future Perspectives

I am also very grateful to the members of the journal’s Honorary Editorial Board, who have acted as peer reviewers and authors, and have provided guidance on journal content, policy, and processes:

• Sathy V. Balu-iyer, School of Pharmacy and Pharmaceutical Sciences, SUNY–University at Buffalo, Buffalo, NY, USA

• Lothar Bergmann, Klinikum der Johann Wolfgang Goethe-Universitat, Frankfurt, Germany

• George D. Demetri, Dana Farber Cancer Institute, Boston, MA, USA

• Erwin Dreesen, KU Leuven, Leuven, Belgium

• Terence R. Flotte, University of Massachusetts Medical School, Worcester, MA, USA

• Timothy M. Ganey, Vivex Biomedical, Atlanta, GA, USA

• Arnold Ganser, Hannover Medical School, Hannover, Germany

• Hans-Peter Gerber, 3T Biosciences, Palo Alto, CA, USA

• Thijs J. Giezen, Foundation Pharmacy for Hospitals in Haarlem, Haarlem, Netherlands

• Bernd Groner, Georg-Speyer-Haus, Institute for Biomedical Research, Frankfurt, Germany

• Francois Guilhot, Université de Poitiers, Poitiers, France

• William H. Hildebrand, University of Oklahoma, Oklahoma City, OK, USA

• Dafne Müller, Universitat Stuttgart, Stuttgart, Germany

• Won Park, Inha University Medical School, Incheon, Republic of Korea

• Cesar Picado, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain

• Thomas Schirrmann, YUMAB GmbH, Braunschweig, Germany

• Susan Sharfstein, SUNY Polytechnic Institute, Albany, NY, USA

• Kichul Shin, SMG-SNU Boramae Medical Center, Seoul, Korea

• Cy A. Stein, City of Hope Medical Center, Duarte, CA, USA

• Raymond C. Stevens, University of Southern California, Los Angeles, CA, USA

• William R. Strohl, BiStro Biotech Consulting, Bridgewater, NJ, USA

• Bruce A. Sullenger, Duke University Medical Center, Durham, NC, USA

• Jonathan Terrett, CRISPR Therapeutics, Inc., Cambridge, MA, USA

• Gianluca Trifirò, University of Verona, Verona, Italy

• Piotr Trzonkowski, Medical University of Gdansk, Gdansk, Poland

• Jos W. van der Meer, Radboud University Medical Center, Nijmegen, the Netherlands

• Elena R. Wolff-Holz, Paul Ehrlich Institut, Langen, Germany

• Gillian Woollett, Samsung Bioepis US, Washington, DC, USA

The editorial program for BioDrugs for 2023 is well under way, and I am looking forward to bringing you many high-quality and authoritative articles in the field of biotechnology-based pharmaceuticals over the coming year.

I thank you for your continued support.

With best wishes,

Kathy Fraser, Editor